Xu, Yanjun
Huang, Zhiyu
Lu, Hongyang
Yu, Xinming
Li, Yuping
Li, Wenfeng
Chen, Jun
Chen, Ming
Gong, Lei
Chen, Kaiyan
Qin, Jin
Xu, Xiaoling
Jin, Ying
Zhao, Jun
Shi, Xun
Han, Na
Xie, Fajun
Zhang, Peng
Xu, Weizhen
Fan, Yun
Article History
Received: 26 May 2019
Revised: 23 August 2019
Accepted: 30 August 2019
First Online: 16 September 2019
Competing interests
: The authors declare no competing interests.
: This study was approved by Medical Ethics Committee of Zhejiang Cancer Hospital with the committee’s reference number: IRB-2016-124. The study was performed in accordance with the Declaration of Helsinki. All enrolled patients provided written informed consent before any study-specific procedures were performed.
: This is investigator initiated trial and Jiangsu Hengrui Pharmaceuticals Company provided apatinib for this study, but was not involved in the study design, data collection, analysis and interpretation, article writing, or the decision to submit for publication. All authors had full access to raw data, and the corresponding author has final responsibility for the publication submission.
: All data included in this study are available upon request by contact with the corresponding author.